Navidea biopharmaceuticals reports second quarter 2022 financial results

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the second quarter and year-to-date for the period ended june 30, 2022. second quarter 2022 highlights and subsequent events continued enrollment into the company's nav3-33 phase 3 trial in rheumatoid arthritis (“ra”) titled “evaluation of tc
NAVB Ratings Summary
NAVB Quant Ranking